Point72 Asset Management
FOLD

Point72 Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Point72 Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$791K Sell
54,677
-2,013,777
-97% -$28.9M ﹤0.01% 2900
2025
Q4 		$29.5M Sell
2,068,454
-5,088,103
-71% -$50M 0.03% 668
2025
Q3 		$56.4M Buy
7,156,557
+3,877,510
+118% +$27.6M 0.09% 242
2025
Q2 		$18.8M Buy
3,279,047
+293,939
+10% +$1.9M 0.04% 526
2025
Q1 		$24.4M Buy
+2,985,108
New +$27.6M 0.06% 395
2024
Q4 		– Sell
-1,266,900
Closed -$13.5M – 2195
2024
Q3 		$13.5M Buy
+1,266,900
New +$13.8M 0.03% 541
2023
Q4 		– Sell
-946,697
Closed -$11.5M – 2364
2023
Q3 		$11.5M Sell
946,697
-6,054,203
-86% -$78.1M 0.03% 597
2023
Q2 		$87.9M Buy
7,000,900
+4,751,772
+211% +$56.4M 0.26% 94
2023
Q1 		$24.9M Buy
+2,249,128
New +$27.7M 0.08% 295
2022
Q4 		– Sell
-1,646,400
Closed -$17.2M – 1608
2022
Q3 		$17.2M Buy
1,646,400
+528,500
+47% +$5.89M 0.07% 363
2022
Q2 		$12M Buy
1,117,900
+642,400
+135% +$5.29M 0.05% 461
2022
Q1 		$4.5M Buy
+475,500
New +$4.46M 0.02% 729
2021
Q3 		– Sell
-3,867,400
Closed -$37.3M – 1110
2021
Q2 		$37.3M Buy
3,867,400
+3,690,078
+2,081% +$36M 0.17% 161
2021
Q1 		$1.75M Buy
+177,322
New +$2.74M 0.01% 746
2020
Q4 		– Sell
-1,541,042
Closed -$21.8M – 989
2020
Q3 		$21.8M Buy
1,541,042
+522,513
+51% +$7.62M 0.11% 255
2020
Q2 		$15.4M Sell
1,018,529
-1,224,371
-55% -$14.9M 0.1% 255
2020
Q1 		$20.7M Buy
+2,242,900
New +$21.3M 0.17% 173
2019
Q4 		– Sell
-1,267,000
Closed -$10.2M – 1046
2019
Q3 		$10.2M Sell
1,267,000
-1,758,664
-58% -$19.1M 0.06% 355
2019
Q2 		$37.8M Buy
+3,025,664
New +$38.4M 0.2% 135
2019
Q1 		– Sell
-3,800,585
Closed -$36.4M – 1088
2018
Q4 		$36.4M Buy
3,800,585
+1,471,385
+63% +$16.2M 0.18% 153
2018
Q3 		$28.2M Buy
2,329,200
+1,621,900
+229% +$22.7M 0.12% 224
2018
Q2 		$11M Buy
+707,300
New +$10.7M 0.04% 421
2018
Q1 		– Sell
-2,870,100
Closed -$41.3M – 998
2017
Q4 		$41.3M Buy
2,870,100
+1,130,654
+65% +$15.5M 0.18% 157
2017
Q3 		$26.2M Sell
1,739,446
-133,654
-7% -$1.77M 0.12% 214
2017
Q2 		$18.9M Sell
1,873,100
-1,127,400
-38% -$9.07M 0.11% 263
2017
Q1 		$21.4M Buy
+3,000,500
New +$19M 0.12% 232
2015
Q3 		– Sell
-916,700
Closed -$13M – 818
2015
Q2 		$13M Buy
916,700
+742,800
+427% +$8.93M 0.09% 276
2015
Q1 		$1.89M Buy
+173,900
New +$1.53M 0.01% 563
2014
Q4 		– Sell
-195,900
Closed -$1.17M – 718
2014
Q3 		$1.17M Buy
+195,900
New +$1.03M 0.01% 544

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Point72 Asset Management's FOLD Position: Q1 2026 in Review

Point72 Asset Management reduced its Amicus Therapeutics (FOLD) stake by 97% in Q1 2026, selling an estimated $28.9M and leaving 54,677 shares worth $791K. The position accounts for ﹤0.01% of the portfolio, ranked #2900.

Point72 Asset Management first reported a position in FOLD in Q3 2014 and has held it in 29 quarters since. The position peaked at $87.9M in Q2 2023. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Point72 Asset Management held 54,677 shares of Amicus Therapeutics worth $791K as of Q1 2026.
  • Point72 Asset Management sold 2,013,777 Amicus Therapeutics shares in Q1 2026, an estimated $28.9M.
  • Amicus Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2900 holding.
  • Point72 Asset Management first reported a position in Amicus Therapeutics in Q3 2014 and has held it in 29 quarters since.
  • Point72 Asset Management's Amicus Therapeutics position peaked at $87.9M in Q2 2023.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.